About: Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain
Creator	Chen, Zhiwei Liu, Li Wang, Haibo Yu, Wenbo Huang, Xiaoxing Lu, Bin
source	Medline; PMC
abstract	The possible bioterrorism threat using the variola virus, the causative agent of smallpox, has promoted us to further investigate the immunogenicity profiles of existing vaccines. Here, we study for the first time the immunogenicity profile of a replication-competent smallpox vaccine (vaccinia Tiantan, VTT strain) for inducing neutralizing antibodies (Nabs) through mucosal vaccination, which is noninvasive and has a critical implication for massive vaccination programs. Four different routes of vaccination were tested in parallel including intramuscular (i.m.), intranasal (i.n.), oral (i.o.), and subcutaneous (s.c.) inoculations in mice. We found that one time vaccination with an optimal dose of VTT was able to induce anti-VTT Nabs via each of the four routes. Higher levels of antiviral Nabs, however, were induced via the i.n. and i.o. inoculations when compared with the i.m. and s.c. routes. Moreover, the i.n. and i.o. vaccinations also induced higher sustained levels of Nabs overtime, which conferred better protections against homologous or alternating mucosal routes of viral challenges six months post vaccination. The VTT-induced immunity via all four routes, however, was partially effective against the intramuscular viral challenge. Our data have implications for understanding the potential application of mucosal smallpox vaccination and for developing VTT-based vaccines to overcome preexisting antivaccinia immunity.
has issue date	2011-06-20(xsd:dateTime)
bibo:doi	10.1155/2011/970424
bibo:pmid	21765641
has license	no-cc
sha1sum (hex)	5c59d9e3c66ccee9b1e671f475954e581af7a320
schema:url	https://doi.org/10.1155/2011/970424
resource representing a document's title	Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain
has PubMed Central identifier	PMC3134386
has PubMed identifier	21765641
schema:publication	J Biomed Biotechnol
resource representing a document's body	covid:5c59d9e3c66ccee9b1e671f475954e581af7a320#body_text
is schema:about of	named entity 'vaccination' named entity 'routes' named entity 'vaccinia' named entity 'immunogenicity' named entity 'data' named entity 'Tiantan' named entity 'Mucosal' named entity 'Vaccine' named entity 'MICE' named entity 'CAUSATIVE AGENT' named entity 'CRITICAL' named entity 'PREEXISTING' named entity 'POTENTIAL' named entity 'INDUCE' named entity 'OVERCOME' named entity 'APPLICATION' named entity 'POSSIBLE' named entity 'HAVE' named entity 'PARTIALLY' named entity 'BETTER' named entity 'SUBCUTANEOUS' named entity 'INDUCING' named entity 'INTRAMUSCULAR' named entity 'VIRAL' named entity 'REPLICATION' named entity 'OUR' named entity 'PROFILE' named entity 'ANTIBODY RESPONSE' covid:arg/5c59d9e3c66ccee9b1e671f475954e581af7a320 named entity 'USING' named entity 'HIGHER' named entity 'POST' named entity 'MUCOSAL' named entity 'INVESTIGATE' named entity 'NEUTRALIZING ANTIBODY' named entity 'SMALLPOX VACCINE' named entity 'MUCOSAL IMMUNIZATION' named entity 'HIGHER' named entity 'COMPETENT' named entity 'DATA' named entity 'ROUTES' named entity 'BIOTERRORISM' named entity 'INDUCED' named entity 'VACCINIA' named entity 'SMALLPOX VACCINE' named entity 'DIFFERENT' named entity 'PROGRAMS' named entity 'MICE' named entity 'OPTIMAL DOSE' named entity 'ALTERNATING' named entity 'FOUND' named entity 'CHALLENGES' named entity 'HERE' named entity 'UNDERSTANDING' named entity 'LEVEL' named entity 'STRAIN' named entity 'SMALLPOX VACCINATION' named entity 'MUCOSAL VACCINATION' named entity 'CHALLENGE' named entity 'STUDY' named entity 'TESTED' named entity 'PARALLEL' named entity 'ORAL' named entity 'ONE TIME' named entity '28I' named entity 'ANTIVIRAL' named entity 'MASSIVE' named entity 'SIX MONTHS' named entity 'DEVELOPING' named entity 'LEVELS' named entity 'NEUTRALIZING ANTIBODIES' named entity 'STRAIN' named entity 'IMMUNOGENICITY' named entity 'INCLUDING' named entity 'THREAT' named entity 'BASED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software